Equity Profile

BMY

Bristol-Myers Squibb Company

Health CarePharmaceuticals$121.2B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market1:00 AM EDT

Bristol-Myers Squibb Beats on EPS, Stock Up 5.21%

Metric	Actual	Expected	Surprise
EPS	$1.58	$1.42	+9.65%
Revenue	N/A	$10.9B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Bristol-Myers Squibb Beats on EPS, Stock Up 5.21%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.58	$1.42	+9.65%
Revenue	N/A	$10.9B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Bristol-Myers Squibb reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 5.21%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors may view the EPS beat as a sign of operational strength, but the lack of revenue data could lead to cautious sentiment moving forward.

Company Snapshot

Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for serious diseases. As a key player in the health care sector, its performance can significantly impact investor sentiment, especially given ongoing trends in biotechnology and personalized medicine.

Key Metrics to Watch

EPS

Earnings per share (EPS) is a crucial indicator of the company's profitability and financial health.

$1.42

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$10.9B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q4 2025, Bristol-Myers Squibb reported an EPS of $1.26, surpassing expectations by 9.28%. The stock reacted positively, gaining 3.30% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Bristol-Myers Squibb to report solid earnings this quarter, with a consensus EPS of $1.42 and revenue of $10.9 billion. The company has a history of exceeding EPS estimates, which could lead to positive market reactions.

Bull Case

If the company beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a significant stock price increase.

Bear Case

Conversely, if the company misses EPS expectations or shows declining revenue, it could raise concerns about its growth prospects and negatively impact the stock.

Key Metrics to Watch

EPS

$1.42

Earnings per share (EPS) is a crucial indicator of the company's profitability and financial health.

Revenue

$10.9B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.42, indicating continued strong performance?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue figures, and do they align with the $10.9 billion consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bristol-Myers Squibb to exceed EPS expectations, given its recent history of strong performance.

Supporting Evidence

Bristol-Myers has a 75% EPS beat rate over the last eight quarters, indicating a strong likelihood of exceeding expectations.

The average 1-day move when they beat is +4.04%, suggesting that positive surprises have historically led to significant stock gains.

Key Risk

If the company reports an EPS below $1.30, it could invalidate the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on both EPS and revenue growth as indicators of Bristol-Myers Squibb's future performance.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case and suggest strong underlying business performance.

Bear Confirmed If

An EPS below $1.30 would support the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±5.4%

Pricing cheap

The options market is pricing in a potential move of about 4.5% in either direction following the earnings report, indicating some uncertainty among investors.

Options are pricing ±4.5% while BMY has averaged ±5.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

23.9%

Calls (875K)P/C Ratio: 2.59Puts (835K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats expectations, history suggests a positive stock reaction of around +4.04%, confirming strong demand for its products.

In-Line / Cautious

If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline in stock price, with historical patterns indicating an average drop of -7.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline advancements.
2Insights into market demand for key products like Opdivo and Eliquis.
3Management's commentary on cost management and operational efficiencies.
4Guidance on future revenue growth and market expansion strategies.
5Responses to questions about competitive pressures in the pharmaceutical industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a crucial indicator of the company's profitability and financial health.

$1.42

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$10.9B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q4 2025, Bristol-Myers Squibb reported an EPS of $1.26, surpassing expectations by 9.28%. The stock reacted positively, gaining 3.30% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a significant stock price increase.

Bear Case

Conversely, if the company misses EPS expectations or shows declining revenue, it could raise concerns about its growth prospects and negatively impact the stock.

Key Metrics to Watch

EPS

$1.42

Earnings per share (EPS) is a crucial indicator of the company's profitability and financial health.

Revenue

$10.9B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.42, indicating continued strong performance?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue figures, and do they align with the $10.9 billion consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bristol-Myers Squibb to exceed EPS expectations, given its recent history of strong performance.

Supporting Evidence

Bristol-Myers has a 75% EPS beat rate over the last eight quarters, indicating a strong likelihood of exceeding expectations.

The average 1-day move when they beat is +4.04%, suggesting that positive surprises have historically led to significant stock gains.

Key Risk

If the company reports an EPS below $1.30, it could invalidate the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on both EPS and revenue growth as indicators of Bristol-Myers Squibb's future performance.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case and suggest strong underlying business performance.

Bear Confirmed If

An EPS below $1.30 would support the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±5.4%

Pricing cheap

The options market is pricing in a potential move of about 4.5% in either direction following the earnings report, indicating some uncertainty among investors.

Options are pricing ±4.5% while BMY has averaged ±5.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

23.9%

Calls (875K)P/C Ratio: 2.59Puts (835K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats expectations, history suggests a positive stock reaction of around +4.04%, confirming strong demand for its products.

In-Line / Cautious

If the results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline in stock price, with historical patterns indicating an average drop of -7.16%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline advancements.
2Insights into market demand for key products like Opdivo and Eliquis.
3Management's commentary on cost management and operational efficiencies.
4Guidance on future revenue growth and market expansion strategies.
5Responses to questions about competitive pressures in the pharmaceutical industry.